40岁前诊断多发性骨髓瘤年轻患者的流行病学特征:法国经验
该研究分析法国15年间214例≤40岁诊断的多发性骨髓瘤患者,其中189例为症状性MM。骨病变、高ISS评分和高危细胞遗传学是预后不良的独立危险因素。
要点
- 骨病变、高ISS评分和高危细胞遗传学是预后不良的独立危险因素。
- 5年相对生存率83.5%,标化死亡比69.9,MM仍显著缩短年轻患者生存。
核心结论
- 年轻MM患者尽管诊断后生存期延长,但MM仍显著缩短其生存。
- 骨病变、高ISS评分和高危细胞遗传学是预后不良的独立危险因素。
研究设计与样本
- 回顾性研究纳入法国15年间214例年龄≤40岁诊断的MM患者,其中189例为症状性MM。
- 中位随访76个月。
主要发现
- 35%患者贫血,17%肾功能不全,13%高钙血症。
- ISS-1占52.4%,ISS-2占27.5%,ISS-3占20.1%;18%患者有高危细胞遗传学[del 17p和/或t(4;14)]。
- 中位总生存14.5年,中位无进展生存41个月。
临床怎么用
- 对年轻MM患者应评估骨病变、ISS分期和高危细胞遗传学以识别高危人群。
- 强化化疗联合自体干细胞移植是年轻MM患者的主要治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing <2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study, we examined 214 patients diagnosed with MM at age ≤40 years over 15 years, in the era of modern treatments. Among them, 189 patients had symptomatic MM. Disease characteristics were similar to older patients: 35% had anemia, 17% had renal impairment, and 13% had hypercalcemia. The staging was ISS-1 in 52.4%, ISS-2 in 27.5%, and ISS-3 in 20.1%. Overall, 18% of patients had high-risk cytogenetics [del 17p and/or t(4;14)]. Ninety percent of patients received intensive chemotherapy followed by autologous stem cell transplant, and 25% of patients had allogeneic stem cell transplant predominantly at time of relapse. The median follow-up was 76 months, the estimated median overall survival was 14.5 years, and the median progression free-survival was 41 months. In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P = .01), high ISS score (HR, 2.14; P = .03), and high-risk cytogenetics (HR, 4.54; P < .0001) were significant risk factors for poor outcomes. Among predefined time-dependent covariables, onset of progression (HR, 13.2; P < .0001) significantly shortened overall survival. At 5 years, relative survival compared with same age- and sex-matched individuals was 83.5%, and estimated standardized mortality ratio was 69.9 (95% confidence interval, 52.7-91.1), confirming that MM dramatically shortens the survival of young patients despite an extended survival after diagnosis.
引用
- Caulier A, Roussel M, Morel P, et al. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021. PMID: 34479366. doi:10.1182/blood.2021011285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。